Literature DB >> 16120073

Potential for drug interactions involving cytochrome P450 in patients attending palliative day care centres: a multicentre audit.

A Wilcock1, J Thomas, J Frisby, M Webster, V Keeley, G Finn, K Fossey, B Wee, J Beale, M S Lennard.   

Abstract

AIM: To determine the potential for drug interactions involving cytochrome P450 (CYP) in patients receiving palliative day care.
METHODS: Drugs used by patients attending four specialist palliative day care centres were reviewed to identify combinations that could result in a pharmacokinetic interaction via any of the five main human forms of CYP.
RESULTS: Of 160 patients, 145 (91%) were prescribed at least one drug that was a substrate, inhibitor or inducer of one of the five main CYP isoforms. Twenty-four drug combinations, involving 34 patients, could have given rise to a clinically important interaction.
CONCLUSIONS: Prescribers should be aware that in this group of patients, one in five are at risk of a clinically important CYP-mediated drug interaction.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16120073      PMCID: PMC1884769          DOI: 10.1111/j.1365-2125.2005.02428.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  9 in total

1.  Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects.

Authors:  L Poulsen; K Brøsen; L Arendt-Nielsen; L F Gram; K Elbaek; S H Sindrup
Journal:  Eur J Clin Pharmacol       Date:  1996       Impact factor: 2.953

2.  Omeprazole inhibits elimination of diazepam.

Authors:  R Gugler; J C Jensen
Journal:  Lancet       Date:  1984-04-28       Impact factor: 79.321

3.  In vivo and in vitro induction of human cytochrome P4503A4 by dexamethasone.

Authors:  J S McCune; R L Hawke; E L LeCluyse; H H Gillenwater; G Hamilton; J Ritchie; C Lindley
Journal:  Clin Pharmacol Ther       Date:  2000-10       Impact factor: 6.875

Review 4.  Drug interactions in palliative care.

Authors:  S A Bernard; E Bruera
Journal:  J Clin Oncol       Date:  2000-04       Impact factor: 44.544

5.  Pharmacokinetic interaction between corticosteroids and tacrolimus after renal transplantation.

Authors:  Dany Anglicheau; Martin Flamant; Marie Hélène Schlageter; Frank Martinez; Bruno Cassinat; Philippe Beaune; Christophe Legendre; Eric Thervet
Journal:  Nephrol Dial Transplant       Date:  2003-11       Impact factor: 5.992

6.  Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.

Authors:  T Heiskanen; K T Olkkola; E Kalso
Journal:  Clin Pharmacol Ther       Date:  1998-12       Impact factor: 6.875

7.  Phenytoin impairs the bioavailability of dexamethasone in neurological and neurosurgical patients.

Authors:  J B Chalk; K Ridgeway; T Brophy; J D Yelland; M J Eadie
Journal:  J Neurol Neurosurg Psychiatry       Date:  1984-10       Impact factor: 10.154

8.  Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards.

Authors:  S J C Davies; S Eayrs; P Pratt; M S Lennard
Journal:  Br J Clin Pharmacol       Date:  2004-04       Impact factor: 4.335

9.  Monitoring drug use in palliative care.

Authors:  R G Twycross; S Bergl; S John; K Lewis
Journal:  Palliat Med       Date:  1994       Impact factor: 4.762

  9 in total
  5 in total

1.  Drug interactions in dying patients: a retrospective analysis of hospice inpatients in Germany.

Authors:  Sebastian Frechen; Anna Zoeller; Klaus Ruberg; Raymond Voltz; Jan Gaertner
Journal:  Drug Saf       Date:  2012-09-01       Impact factor: 5.606

2.  The Burden of Polypharmacy in Patients Near the End of Life.

Authors:  Michael J McNeil; Arif H Kamal; Jean S Kutner; Christine S Ritchie; Amy P Abernethy
Journal:  J Pain Symptom Manage       Date:  2015-09-30       Impact factor: 3.612

Review 3.  Prevalence of drug interactions in hospital healthcare.

Authors:  María Espinosa-Bosch; Bernardo Santos-Ramos; María Victoria Gil-Navarro; María Dolores Santos-Rubio; Roberto Marín-Gil; Paloma Villacorta-Linaza
Journal:  Int J Clin Pharm       Date:  2012-09-11

Review 4.  Current and Emerging Options in the Management of EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Considerations in the Elderly.

Authors:  Gabriele Minuti; Armida D'Incecco; Federico Cappuzzo
Journal:  Drugs Aging       Date:  2015-11       Impact factor: 3.923

Review 5.  The treatment of metastatic non-small cell lung cancer in the elderly: an evidence-based approach.

Authors:  David E Dawe; Peter Michael Ellis
Journal:  Front Oncol       Date:  2014-07-10       Impact factor: 6.244

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.